Events & Conferences

In this section, explore the key scientific events and conferences where Clinisciences takes center stage—whether as a sponsor or an active participant. From high-impact international congresses to focused expert symposia, our presence reflects our dedication to advancing research and connecting with the scientific community. These events are more than just dates on a calendar—they're opportunities to exchange ideas, showcase innovative tools, and stay at the forefront of scientific discovery. Join us where breakthroughs happen!

Quimigen at ICB CDT Chemical Biology Conference 2026

Quimigen is pleased to participate as a sponsor at the ICB CDT Chemical Biology Conference 2026, taking place on Monday 13 July 2026 at Imperial College London, United Kingdom. This focused event brings together students, researchers and industry professionals to exchange on the latest advances in chemical biology.

Quimigen at the Technician Partnership Conference 2026

Quimigen is pleased to participate as a sponsor at the Technician Partnership Conference 2026, taking place on 1 July 2026 at Newcastle University, United Kingdom. This national event brings together technical professionals to discuss research culture, professional development and innovation in laboratory environments.

Quimigen at RBMP 2026 – XVIII Meeting of Plant Molecular Biology

Quimigen is delighted to participate as a sponsor and exhibitor at the RBMP 2026, the XVIII Meeting of Plant Molecular Biology, taking place from 1 to 3 July 2026 in Bilbao, Spain. We look forward to meeting the scientific community and showcasing our latest solutions for plant research and biotechnology.

Press Release: Genexpath joins Quimigen Group

A Quimigen reforça a sua liderança em biologia molecular e hemato-oncologia com a aquisição estratégica da Genexpath, especialista em soluções de diagnóstico in vitro para linfomas e sarcomas.

Comunicado de imprensa: Oncomedics junta-se ao Grupo Quimigen

O Quimigen Group, distribuidor europeu de reagentes e equipamentos para a investigação científica e o diagnóstico médico, adquiriu a Oncomedics, uma empresa francesa de biotecnologia especializada na personalização de tratamentos contra o cancro.